[8-K] Aptevo Therapeutics Inc. Reports Material Event

Rhea-AI Filing Summary

Aptevo Therapeutics entered into Amendment No. 5 to its Rights Agreement, extending the definition of the “Final Expiration Date” to October 29, 2026. The Rights Agreement covers contingent rights to purchase one one‑thousandth of a share of the company’s Series A Junior Participating Preferred Stock. The change is disclosed as a material modification to security holder rights under Item 3.03.

Insights

Corporate governance analyst

Extension of shareholder rights plan; administrative, neutral impact.

Aptevo Therapeutics extended the Rights Agreement’s Final Expiration Date to October 29, 2026. The agreement provides contingent rights tied to one one‑thousandth of a share of Series A Junior Participating Preferred Stock, preserving the framework already in place.

The filing lists this as a material modification of security holder rights (Item 3.03), but it does not introduce new economic terms in the excerpt. Actual impact depends on future circumstances that could activate the contingent rights; none are indicated here.

false000167158400016715842025-10-302025-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On October 30, 2025, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 5 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (as amended and/or restated from time to time, the “Rights Agreement”). The Rights Agreement pertains to those certain contingent rights to purchase one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001, of the Company (each, a “Preferred Share”).

The Amendment extends the definition of “Final Expiration Date” (as defined in the Rights Agreement) and certain related language in the Rights Agreement to October 29, 2026.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is attached as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.03 Material Modification to Rights of Security Holders.

The information set forth under “Item 1.01 Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Number	Description
4.1	Amendment No. 5 to Rights Agreement, dated as of October 30, 2025, between the Company and Broadridge Corporate Issuer Solutions, LLC, as Rights Agent
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	October 30, 2025	By:	/s/ Marvin L. White
			Marvin L. White President and Chief Executive Officer

FAQ

What did APVO disclose in its 8-K?

Aptevo entered into Amendment No. 5 to its Rights Agreement, extending the “Final Expiration Date” to October 29, 2026.

What does the Rights Agreement cover for APVO?

It pertains to contingent rights to purchase one one‑thousandth of a share of Series A Junior Participating Preferred Stock.

Is this a material change to security holder rights for APVO?

Yes. It is reported under Item 3.03 as a material modification to rights of security holders.

What is the new Final Expiration Date for APVO’s rights plan?

The Final Expiration Date is extended to October 29, 2026.

Did APVO disclose financial terms or proceeds related to this change?

The excerpt describes an extension of the expiration date; it does not include financial proceeds or pricing terms.

Which exhibit contains the amendment for APVO?

Exhibit 4.1 contains Amendment No. 5 to the Rights Agreement dated October 30, 2025.